Last updated: 2026-09-22 20:01:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Creative Medical Technology Holdings, Inc. (CELZ) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $0.92, with a market capitalization of $6.37M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.62 to $6.25. This page covers its latest market performance, valuation, price trends and company information.
$6.37M | |
$0.88 | |
$51.45 | |
$0.62 | |
$1.00 | |
1.70M | |
10.00M | |
-- | |
$6.25 | |
$0.62 | |
-- | |
-- |
Creative Medical Technology Holdings, Inc. (CELZ) is trading at $0.92 in after-hours trading as of 2026-09-22 19:59:00, down 8.36% ($0.08) from the regular-session close of $1.01.
After-hours trading shows how investors are pricing CELZ after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Creative Medical Technology Holdings, Inc. (CELZ) moved from $0.96 to $0.92, representing a decline of 4.12% ($0.04).
The stock traded between $0.81 and $1.04 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 3.02 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 5.3%
CELZ is currently trading at $0.92, placing it 5.3% of the way from its 52-week low of $0.62 to its 52-week high of $6.25. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 4 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Creative Medical Technology Holdings, Inc. (CELZ) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.